JP2007534772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007534772A5 JP2007534772A5 JP2007510987A JP2007510987A JP2007534772A5 JP 2007534772 A5 JP2007534772 A5 JP 2007534772A5 JP 2007510987 A JP2007510987 A JP 2007510987A JP 2007510987 A JP2007510987 A JP 2007510987A JP 2007534772 A5 JP2007534772 A5 JP 2007534772A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- polypeptide
- group
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 239000003814 drug Substances 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 12
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 102100022695 Histidine ammonia-lyase Human genes 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000002271 resection Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108700006308 Histidine ammonia-lyases Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical group C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56568804P | 2004-04-27 | 2004-04-27 | |
| PCT/US2005/014668 WO2005104785A2 (en) | 2004-04-27 | 2005-04-27 | Methods and compositions for specifically targeting human hepatocellular carcinoma cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007534772A JP2007534772A (ja) | 2007-11-29 |
| JP2007534772A5 true JP2007534772A5 (enExample) | 2008-06-19 |
Family
ID=35242179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510987A Pending JP2007534772A (ja) | 2004-04-27 | 2005-04-27 | ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080152650A1 (enExample) |
| EP (1) | EP1755669A4 (enExample) |
| JP (1) | JP2007534772A (enExample) |
| WO (1) | WO2005104785A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| CA2653967A1 (en) * | 2006-06-02 | 2008-10-02 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| EP2388338A1 (en) * | 2010-04-30 | 2011-11-23 | Medizinische Hochschule Hannover | Method for determination of and medicament for influencing the activity of the immune system |
| SI3673080T1 (sl) * | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| CN114935651A (zh) * | 2022-04-27 | 2022-08-23 | 广州源康生物医药科技有限公司 | 一种肿瘤生物标志物及应用 |
| WO2024180461A1 (en) * | 2023-02-27 | 2024-09-06 | Ebrahiminik Hojat | Integrated system for ethanol ablation and radiofrequency ablation of thyroid nodules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0984984A2 (en) * | 1997-06-03 | 2000-03-15 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
| EP1217066A1 (en) * | 2000-12-21 | 2002-06-26 | Universiteit Gent | Modulation of ATP-binding cassette transporter activity |
| US20040068096A1 (en) * | 2001-09-21 | 2004-04-08 | Zenta Tsuchihashi | Human single nucleotide polymorphisms in organic anion transport and multi-drug resistant proteins |
| US20060046249A1 (en) * | 2002-01-18 | 2006-03-02 | Fei Huang | Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways |
| WO2003083046A2 (en) * | 2002-03-08 | 2003-10-09 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| CN1659287A (zh) * | 2002-04-05 | 2005-08-24 | 美国政府健康及人类服务部 | 诊断肝癌转移或发病可能性及鉴定治疗靶点的方法 |
-
2005
- 2005-04-27 WO PCT/US2005/014668 patent/WO2005104785A2/en not_active Ceased
- 2005-04-27 JP JP2007510987A patent/JP2007534772A/ja active Pending
- 2005-04-27 US US11/568,389 patent/US20080152650A1/en not_active Abandoned
- 2005-04-27 EP EP05749453A patent/EP1755669A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rutkowska et al. | EGFRvIII: an oncogene with ambiguous role | |
| AU2008204486B2 (en) | Dbait and its standalone uses thereof | |
| Chen et al. | Novel strategies for the treatment of chondrosarcomas: targeting integrins | |
| US20120171201A1 (en) | Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | |
| RU2013129450A (ru) | Способ лечения опухолей с применением vegf-специфических антагонистов | |
| WO2003034903B1 (en) | Psma antibodies and protein multimers | |
| JP2011526626A5 (enExample) | ||
| JP2008507536A5 (enExample) | ||
| JP2006525796A5 (enExample) | ||
| JP7289029B2 (ja) | 分子誘導システムペプチド及びその使用 | |
| CN104411825B (zh) | 骨膜蛋白适配体及包含其的抗癌组合物 | |
| JP2019506862A5 (enExample) | ||
| JP2002505841A5 (enExample) | ||
| US20160200783A1 (en) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation | |
| KR20120048613A (ko) | Ｓｐａｒｃ 안티센스 조성물과 이들의 용도 | |
| Lin et al. | Role of spinal CXCL1 (GROα) in opioid tolerance: a human-to-rodent translational study | |
| JP2007534772A5 (enExample) | ||
| Tan et al. | Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities | |
| CA2666184A1 (en) | The use of a dna damaging agent and a ligand for the treatment of cancer | |
| WO2014173859A2 (en) | Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections | |
| EP3969000A1 (en) | Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation | |
| US12162874B2 (en) | Peptidomimetic-based antibody surrogate for HER2 | |
| US20100247525A1 (en) | Compositions and methods for treating anthrax lethality | |
| KR20220001481A (ko) | 혈액-뇌 장벽 침투 압타머 및 이의 이용 | |
| KR20170052454A (ko) | 소라페닙 민감성 예측용 바이오마커 조성물 |